

SENTARA HEALTH PLANS

MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-844-668-1550.** No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. If information provided is not complete, correct, or legible, authorization can be delayed.

For Medicare Members: Medicare Coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <https://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx>. Additional indications may be covered at the discretion of the health plan.

The Sentara Health Plans Oncology Program is administered by OncoHealth

- ❖ **For any oncology indications**, the most efficient way to submit a prior authorization request is through the **OncoHealth OneUM Provider Portal** at <https://oneum.oncohealth.us>. Fax to **1-800-264-6128**.
OncoHealth can also be contacted by Phone: 1-888-916-2616.
- ❖ Commercial customers **NOT** enrolled in the OncoHealth program, please fax requests to Sentara Health plans at fax number 1-844-668-1550.

Somatostatin Analog Drugs (Medical)

Drug Requested: Check box below that applies.

<input type="checkbox"/> lanreotide acetate extended release SQ injection 120 mg/0.5 mL (J1932)	<input type="checkbox"/> octreotide injection (generic Sandostatin®) (J2354)
<input type="checkbox"/> Sandostatin® (octreotide) injection (J2353)	<input type="checkbox"/> Signifor LAR® (pasireotide) SQ injection (J2502)
<input type="checkbox"/> Somatuline® Depot (lanreotide) injection 60 mg, 90 mg, 120 mg (J1930)	

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

NPI #: _____

(Continued on next page)

DRUG INFORMATION: Authorization may be delayed if incomplete.**Drug Name/Form/Strength:** _____**Dosing Schedule:** _____ **Length of Therapy:** _____**Diagnosis:** _____ **ICD Code, if applicable:** _____**Weight (if applicable):** _____ **Date weight obtained:** _____

Standard Review. In checking this box, the timeframe does not jeopardize the life or health of the member or the member's ability to regain maximum function and would not subject the member to severe pain.

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Diagnosis: Acromegaly (lanreotide, octreotide, Sandostatin, Signifor LAR, Somatuline)

Initial Authorization: 12 months

Member is 18 years of age or older

AND

Provider is an endocrinologist or neurosurgeon

AND

Member has undergone pituitary surgery and/or irradiation is contraindicated (**chart notes must be submitted to document diagnosis and surgical history or contraindication to surgery**

AND

Diagnosis confirmed by elevated IGF-1 levels as well as inadequate suppression of growth hormone (GH) levels (**current labs must be submitted for documentation**)

AND

For Signifor LAR and Somatuline Depot: Medication will not be used in combination with long-acting somatostatin analogs

Diagnosis: Acromegaly (lanreotide, octreotide, Sandostatin, Signifor LAR, Somatuline)

Reauthorization: 12 months

No toxicity has been observed while taking the requested medication

(Continued on next page)

AND

- Response is demonstrated by **BOTH** of the following (**Chart notes and current lab test results must be submitted for documentation**)
 - Reduction of GH levels from pre-treatment baseline
 - Normalization of IGF-1 level

□ Diagnosis: Cushing's Disease (Signifor LAR)

Initial Authorization: 3 months

- Member is 18 years of age or older

AND

- Provider is an endocrinologist or neurosurgeon

AND

- Member has a diagnosis of Cushing's disease and pituitary surgery is not an option or has not been curative (**chart notes must be submitted to document diagnosis and surgical history or contraindication to surgery**)

AND

- Member's baseline 24-hour urinary free cortisol level is greater than 1.5 times the upper limit of normal (**labs must be submitted for documentation**)

AND

- Current baseline labs are attached documenting **ALL** the following: liver function tests, fasting plasma glucose, hemoglobin A1c, thyroid function, baseline ECG, and gallbladder ultrasound

□ Diagnosis: Cushing's Disease (Signifor LAR)

Reauthorization: 12 months

- Member's current 24-hour urinary free cortisol level is below the upper limit of normal mean (**labs must be submitted for documentation**)

AND

- Current labs documenting member's liver function, fasting plasma glucose and hemoglobin A1c are attached

(Continued on next page)

AND

Improvements in blood pressure, triglycerides, low-density lipoprotein cholesterol, weight and health related quality of life have been maintained while on Signifor therapy (**Chart notes must be submitted for documentation**)

Diagnosis: Other

Please submit documentation showing medical necessity

Medication being provided by (check box below that applies):

Location/site of drug administration: _____

NPI or DEA # of administering location: _____

OR

Specialty Pharmacy

For urgent reviews: Practitioner should call Sentara Health Plans Pre-Authorization Department if they believe a standard review would subject the member to adverse health consequences. Sentara Health Plan's definition of urgent is a lack of treatment that could seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.